Back at the church at 11:47 PM, Karen spread the documents on the Sunday school table under the light from two phones held flat by Carl and Bradley, who held them perfectly still with the focused seriousness of men performing an important and achievable task.
The documents were old. Not ancient — fourteen years old, twelve, eleven — but old in the way that paper gets old when it's been filed in a climate-controlled cabinet rather than digitized, the edges crisp, the print clean, the entire physical existence of the documents arguing that Karen had believed from the first day that some things needed to exist outside of servers.
"Explain what I'm looking at," Kevin said.
Karen sorted them into three groups. Her hands moved with the efficiency of someone who had filed and retrieved these documents in drills that Kevin had not known were drills.
"This group: internal BioVance financial records from years four through eight of the LZR project. The official records show standard pharmaceutical R&D expenditures — lab supplies, personnel, regulatory compliance, clinical trial infrastructure. The actual records, which I maintained in the overflow cabinet using a secondary code system that the standard audit process wouldn't recognize as financial documents—" She tapped the first stack. "Show that the R&D budget had a shadow line item. Not small. Six hundred and twelve million dollars over eight years, classified internally as 'Strategic Partnership Initiative.'"
"Six hundred million dollars," Marcus said. He was leaning over the table, reading upside down.
"Six hundred and twelve. The Strategic Partnership Initiative funded Meridian's weapons adaptation division, which took the pharmaceutical-grade LZR-7 research and applied it to aerosol delivery mechanisms, dispersal modeling, and the containment breach protocols that allow for a controlled release in a civilian environment." She moved to the second stack. "This group: contract documents. The actual Meridian-BioVance agreement, which the official records show as a 'research and development services agreement' and which is actually a weapons licensing contract with deployment rights and liability clauses. The liability clauses are the interesting part — BioVance indemnified Meridian for any 'collateral civilian outcomes' resulting from deployment in authorized scenarios."
"Collateral civilian outcomes," Derek said. He was standing at the back of the room, arms folded.
"The legal language for what happened — almost happened — yesterday afternoon in downtown Sacramento."
Priya had said nothing for two minutes. She was standing near the door, watching the documents spread on the table, and the expression on her face had the quality that Kevin associated with the moments when Priya's professional composure met something that genuinely unsettled it.
"The third group?" Kevin asked.
Karen's hand rested on the third stack without picking it up. A pause that was different from Karen's usual pauses — not calculation, something else. "The third group contains documents relating to a second facility."
"A second BioVance facility."
"Not a BioVance facility. The BioVance operation was the originating laboratory. The pathogen development happened there. What the third group documents is the downstream operation — the facility where the weapons-grade variant was produced at scale." She looked at Kevin. "Greenfield, Oregon was the initial uncontrolled release. Sacramento was the planned deployment. Those two events were the entire scope of what we understood. These documents describe a third site."
The room was quiet. The sound of the church's HVAC running.
"Where?" Kevin asked.
"The documents are deliberately incomplete. The site is referred to only as 'Facility Gamma.' The location is encoded — the encoding system I didn't design, so I can't read it without the cipher key. What I can read is the scale." Karen picked up the top sheet of the third stack. "Facility Gamma's production logs show a pathogen yield three times the volume of the Sacramento deployment. The Sacramento aerosol load was calibrated for an urban target of approximately two hundred thousand. Facility Gamma's yield is calibrated for approximately six hundred thousand."
No one spoke.
"Six hundred thousand target population," Rachel said. The words came out slowly, the pace of someone who was saying something that needed to be said slowly to be heard correctly. "That's not Sacramento. That's—"
"That's the next operation," Karen said. "The Sacramento deployment was a test. A proof of concept on a mid-sized urban target. Facility Gamma is the operational scale-up."
Kevin looked at the documents. At the numbers in Karen's meticulous secondary code system. At the fourteen years of financial records that encoded a weapons program in accounting language so dry and specific that a BioVance audit team had reviewed these records twelve times without noticing what they contained.
He picked up his phone. The time was 11:59 PM.
"Marcus," he said. "Get Linda. Get everyone who's still awake. We need to have a conversation."
---
Linda arrived at the church at 1:15 AM. She drove a faculty parking permit-stickered Subaru and she walked into the Sunday school room with the expression of a woman who'd been asleep for two hours for the first time in four days and who had accepted that sleep was a temporary state.
Kevin walked her through the documents. Karen provided context. Marcus provided the technical translation for sections that used language designed to obscure. By 2 AM, Linda had read the three stacks and was sitting with her elbows on the children's table looking at a crayon drawing of the Sermon on the Mount.
"Facility Gamma," she said.
"We can't locate it without the cipher key. The financial records give us the production scale. The contract documents give us the deployment timeline." Kevin tapped the third stack. "The deployment timeline shows Facility Gamma as Phase Four. Sacramento was Phase Three. There were Phase One and Two that preceded it."
"What were One and Two?"
Karen said: "Phase One was the initial controlled release at a facility in rural Nevada. The population was eight hundred. The containment breach was described as a 'validation test.' Phase Two was Greenfield, Oregon."
The silence in the room had density.
"Greenfield was Phase Two," Kevin said. "Not an accident. Not an escape. A Phase Two validation test. They released the pathogen in a town of six thousand people to test the spread pattern and the containment protocols."
Linda's hands were flat on the table. Not moving. The very still quality that Linda had when she was processing something that was restructuring the model she'd built.
"We knew BioVance created the pathogen," she said. "We knew Meridian weaponized it. We thought the outbreak was an accident." She paused. "It wasn't."
"Nothing was an accident," Karen said. "The wild spread from Oregon — the pathogen moving south, the containment perimeter failing — that's not a containment failure. That's the secondary spread from Phase Two behaving exactly as the models predicted. The models that BioVance funded and Meridian validated."
Kevin looked at Linda. At the woman who'd been a veterinary professor three days ago and who was now sitting in a church Sunday school room at 1:15 AM reading the documents that explained what had happened to the world she'd been living in.
"The FBI needs all of this," Linda said.
"Yes."
"Tonight."
"Tomorrow morning. The FBI field office opens at—"
"Agent Morrison gave me her personal number." Linda stood up. She picked up her phone. "She gave it to me after the Mather Field inspection because she said — her exact words — 'if you find anything else, don't wait for business hours.'" She looked at Kevin. "I'm going to call her now."
Kevin nodded. Linda stepped out of the room.
Through the door, faintly: "Agent Morrison. This is Dr. Linda Park from UC Davis. I'm sorry for the time. I'm with the group that stopped the Sacramento deployment. We have documents you need to see. Tonight." A pause. "Yes. I'll text you the address."
Kevin looked at the three stacks of documents. At the financial records that encoded six hundred and twelve million dollars of weapons funding as Strategic Partnership Initiative. At the liability clauses that called two hundred thousand potential dead people "collateral civilian outcomes."
"There's another one," Rachel said. She was looking at the third stack. "There's a Phase Four operation that's already built and loaded and ready to go. And we still don't know where it is."
"We know it exists," Kevin said. "Yesterday morning we didn't even know that."
"That's not as comforting as you mean it to be."
"No," he said. "It isn't."
He sat down on one of the child-sized chairs. His knee had moved past the point of filing grievances and into a state of something that Paul would describe as "the joint communicating through a different channel." He elevated the leg on the adjacent chair and looked at the ceiling.
The ceiling had a water stain in the shape of nothing in particular. Churches, Kevin thought, had a higher tolerance for imperfect infrastructure than corporations, which said something about the relative priorities of each and which side of that comparison produced buildings that were still functional twenty-two days after everything changed.
"The cipher key," Kevin said. "The encoding system on the Facility Gamma documents. Where would it be?"
Karen sat down. "In BioVance's system. Not the accounting system — I wouldn't have access to it. The cipher key would be in the hands of the people who created the documents. The board. Harrison Vance, specifically — his signature is on two of the contract documents."
"Harrison Vance is in custody?"
"Harrison Vance was at BioVance's executive retreat when the outbreak happened. The same retreat we were at." She paused. "The executive floor is separate from the conference areas. The board had their own section of the building. Fourteenth floor, opposite end from accounting."
Kevin looked at her. "The same building."
"The same building."
"Vance might be alive in there."
"He might be." Karen's expression was the expression of someone who had already run this calculation and was watching Kevin arrive at the same output. "If he's alive, he has the cipher key. The cipher key gives us Facility Gamma's location. Facility Gamma's location prevents Phase Four."
"And getting to Harrison Vance means going back into the conference center."
"Going to the executive floor," Karen said. "Which is on the opposite side of the building from accounting. Which has not been surveyed. Which has been occupied by whatever remains of BioVance's board of directors for twenty-two days."
Kevin looked at the legal pad. The conference center floor plan he'd been drawing for two days now had a new section.
"One thing at a time," he said. "Agent Morrison first. Facility Gamma after."
He picked up his pen and added to the floor plan.
The fourteenth floor now had two sections marked. One labeled "accounting" with a checkmark. One labeled "executive" with a question mark and, below it, underlined: *Harrison Vance.*
---
Agent Morrison arrived at the church at 3:45 AM with two other agents and a face that said she'd been awake since before Kevin called and was used to it.
She looked at the documents for ninety minutes. She spoke to Karen for forty minutes about the accounting codes. She made one phone call that Kevin wasn't allowed to hear.
When she came back, she sat across from Kevin at the children's table with her hands folded and the expression of a woman who had been a federal agent for nineteen years and who had, in those nineteen years, developed a specific face for the moments when evidence changed the scale of an investigation.
"The Sacramento deployment was Phase Three," she said.
"Yes."
"Phase One was Nevada. Phase Two was Oregon."
"Yes."
"This document—" She touched the third stack. "References a Phase Four. Facility Gamma. With a production scale three times the Sacramento deployment."
"Yes."
"And you don't know where it is."
"No."
She looked at him for a long moment. The church was quiet. The fellowship hall's overnight population was sleeping. A dog — one of the three — had found a way into the room and was sitting near the door watching everyone, the dog's calm in contrast with the conversation's lack of it.
"What do you know?" Morrison asked.
Kevin pointed at the floor plan.
"The conference center," he said. "Harrison Vance is alive in that building. He has the cipher key. With the key, you can locate Facility Gamma." He looked at her. "We're going back in."
Morrison looked at the floor plan. At the building she'd been briefed on three days ago as a "site of potential evidence" and that was now a building where the chair of a pharmaceutical company that had run a multi-phase bioweapon program might be alive on the executive floor.
"I need to brief my SAC," she said.
"How long will that take?"
"Hours. Maybe a day."
Kevin thought about the wild spread. Nine days, by Marcus's new calculations, before the leading edge of the natural spread reached Sacramento's northern suburbs.
"You have six hours," he said.
Morrison looked at him with the expression she'd worn at the press conference — the face that had declined three hundred professional smiles.
"I need eight," she said.
"Six and a half," Kevin said.
A pause. The shape of a negotiation.
"Seven," Morrison said.
"Done."
